Peptomyc’s Post

Big patent news for Vidac Pharma! The US patent office have issued a notice of allowance for the group of molecules that are the active compound in Vidac Pharma’s cancer drug candidates. “This U.S. patent goes to the heart of Vidac’s efforts to develop an entirely new class of cancer drugs for patients,” said Vidac Chief Executive Officer Prof. max herzberg. The patent will protect Vidac’s two drug candidates – VDA-1102 and VDA-1275 – which the company is developing to use in a wide range of tumors. Vidac’s family of molecules reverse the abnormal metabolism of cancer cells by dislodging the wrongly attached Hexokinase-2 enzyme from the mitochondrial VDAC pores. This stops rapid cell proliferation, restores immune-sensitivity and programmed cell death. Read our press release, more about the science behind our therapies, and the clinical results on our website: www.vidacpharma.com #biotech #oncology #drugdevelopment #bioscience #cancer

G1 Therapeutics and Pepper Bio Announce Ink Global License Agreement for Lerociclib - HIT Consultant #Global License Agreement: G1 Therapeutics and Pepper Bio have announced a global license agreement for Lerociclib, a promising new drug in the field of oncology. This agreement will allow for the development and commercialization of Lerociclib on a global scale. #Lerociclib Overview: Lerociclib is a novel CDK4/6 inhibitor that has shown promising results in preclinical studies. It has the potential to be a game-changer in the treatment of various types of cancer, including breast cancer and lung cancer. #Benefits of Lerociclib: Lerociclib offers several potential benefits over existing CDK4/6 inhibitors, including increased potency, improved safety profile, and enhanced efficacy ai.mediformatica.com #cancer #clinical #livercancer #clinicaltrials #asia #cancertreatment #drugdiscovery #licensing #oncology #breastcancer #radiation #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3JG8rwH)

Personalis, Inc. and Myriad Genetics have announced a cross-licensing agreement to enhance their operations and elevate MRD cancer testing results. For more details on this partnership and their previous collaborations, check out Precision Medicine Online's story! #MRD #Partnership #Oncology #MRDTest #CancerTest #PrecisionOncology

In an effort to bolster both companies' efforts and improve operations in the MRD cancer testing space, Personalis, Inc. and Myriad Genetics have entered a cross-licensing agreement. GenomeWeb has the details, including past partnerships between the companies: #MRD #Partnership #Oncology #MRDTest #CancerTest #PrecisionOncology

Isosterix, founded by Roopa Rai PhD, is breaking new ground in cancer research with their innovative small-molecule inhibitors targeting the KAT6A oncogene. Dr. Rai highlights the impact: “CDD Vault expedites drug discovery by giving you the ability to quickly visualize your data and propose the next molecule to make.” Discover more about Isosterix’s journey and how CDD Vault has impacted their mission: https://lnkd.in/gE8ujWVx

📣 Calidi Biotherapeutics is thrilled to have presented CLD-101 phase 1 trial update and preclinical data highlighting RTNova and CLD-201 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Read more below for key highlights from Calidi's three presentations at ASCO: #calidi #ASCO #stemcells #endcancer $CLDI

I'm delighted to announce the publication of our paper, titled "Conjugation of Doxorubicin and Carbon-based Nanostructures for Drug Delivery Against HT-29 Colon Cancer Cells," in the Journal of Combinatorial Chemistry & High Throughput Screening. This achievement wouldn't have been possible without the unwavering support and dedication of Dr. Fereshteh Chekin, Dr. Kaveh Jafari, and all our co-authors. You can access the full article online through the following DOI link: [https://lnkd.in/daX9QQEf). #nanomedicine #coloncancer #nanoscience

Antibody-drug conjugates (ADCs) are transforming personalized oncology by enabling precise drug delivery to cancer cells, thereby optimizing efficacy and minimizing off-target effects. However, existing in vitro preclinical models fall short in capturing the complexity of tumor heterogeneity, which is crucial for accurately assessing ADCs' potential. We understand the difficulties and limitations so we develop Single-AI Chip, to provide unprecedented resolution at single cell response to study antigen heterogeneity and drug resistance at early preclinical stage of ADC candidate development. It’s time to upgrade your preclinical testing pipeline and select the best candidates for clinical trials!! “Make you testing precise with Provectus Therapeutics.”

Innate Pharma presents preclinical efficacy of its pre-IND drug candidate IPH45, a novel Nectin-4 Antibody Drug Conjugate at American Association for Cancer Research 2024. ➡️ IPH45 is a novel and differentiated Exatecan-ADC targeting Nectin-4 ➡️ In preclinical PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting Enfortumab Vedotin (EV). IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models ➡️ Preclinical efficacy and toxicology data support further development of IPH45 which is progressing towards the clinic with IND planned in 2024 Read the press release: https://lnkd.in/egZY-xjP #InnatePharma #AACR2024 #Immunotherapy #Oncology

Successful preclinical testing of your investigational cancer therapy depends on choosing the right model. Learn more by downloading our white paper! https://hubs.ly/Q02rJrvQ0 #Inotiv #Oncology #R2G2mouse